Alcon Inc. Newsletter
-
Ophthalmic Knives Market Poised for Steady Growth Amid Rising Global Eye Surgeries
17 Jun 2025 17:49 GMT
PORTLAND, OR, UNITED STATES, June 17, 2025 /EINPresswire.com/ -- The global ophthalmic knives market, valued at $385.70 million in 2023, is on track to reach $565.88 million by 2032, growing at a CAGR of 4.3% from 2024 to 2032. This growth …
-
Alcon Receives FDA Approval for Tryptyr to Treat Dry Eye Disease
30 May 2025 10:26 GMT
… the first FDA-approved prescription pharmaceutical from Alcon since the company became … Novartis. Alcon acquired Tryptyr through its 2022 acquisition of Aerie Pharmaceuticals in …
-
FDA Approves Alcon’s Tryptyr for Dry Eye Disease
29 May 2025 23:14 GMT
… their Alcon sales rep for pricing information."
The drug’s … approval was supported by data from Alcon’s … in current treatment options, Alcon has the potential to capitalize … increase over the previous year—Alcon has the infrastructure and …
-
US FDA approves Alcon’s Tryptyr ophthalmic solution for Dry Eye Disease
30 May 2025 11:51 GMT
Alcon has received the US Food and Drug Administration (FDA) … enhanced basal tear production.
Alcon CEO David Endicott said: … for Alcon as Tryptyr becomes our first prescription pharmaceutical … post-treatment initiation.
Alcon anticipates to launch Tryptyr …
-
FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease
29 May 2025 13:01 GMT
… for Alcon as Tryptyr becomes our first prescription pharmaceutical treatment … or increased tear evaporation; Alcon targeted the former with … tear production. However, Alcon reports that the exact … MA.
3. Maharjan, EK. Alcon reports positive results from phase …
-
Alcon gains first FDA prescription drug nod since Novartis split, scoring with drops for dry eye disease
29 May 2025 23:23 GMT
… specialist Alcon has gained its first FDA approval for a prescription drug … for eight years, Alcon split from the Swiss pharma giant in 2019 … with struggling Kala Pharmaceuticals.
In addition, two months ago, Alcon secured a …
-
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
29 May 2025 17:31 GMT
… . Food and Drug Administration (FDA) on Wednesday approved Alcon Plc’s ALC … milestone for Alcon as Tryptyr becomes our first prescription pharmaceutical treatment to … LADX resubmission of the New Drug Application (NDA) of reproxalap, an …
-
Drug Device Combination Products Market Report 2025: Injectable, Transdermal Patch, Infusion Pump, Drug-eluting Stent, Inhaler Forecasts to 2030 - ResearchAndMarkets.com
29 May 2025 14:05 GMT
… Transdermal Patch, Infusion Pump, Drug-eluting Stent, Inhaler), Application … Key Technologies
Wearable Technologies
Drug-Eluting Technologies
Complementary Technologies … Limited
Sparsha Pharma International Pvt. Ltd.
Supernus Pharmaceuticals, Inc.
Alcon Inc. …
-
US FDA approves Alcon’s new dry-eye drug
28 May 2025 22:45 GMT
… Reuters) -Eye-care drugmaker Alcon said on Wednesday that … U.S. Food and Drug Administration has approved its treatment … treated with a prescription product.
Alcon, which produces contact lenses, … approved treatments for DED include Alcon’s Eysuvis and Bausch + …
-
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
28 May 2025 20:48 GMT
… the U.S. Food and Drug Administration (FDA) has approved … milestone for Alcon as TRYPTYR becomes our first prescription pharmaceutical treatment … www.accessdata.fda.gov/drugsatfda_docs/label… .gov).
Improved Dry Eye Drugs for 2022 and Beyond; https …
About
© 1995-2025